Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71] (S0302283817300994) (10.1016/j.eururo.2017.02.010))

Bernard Escudier*, Padmanee Sharma, David F. McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Howard Gurney, Frede Donskov, Katriina Peltola, John Wagstaff, Thomas C. Gauler, Takeshi Ueda, Huanyu Zhao, Ian M. Waxman, Robert J. Motzer

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

1 Scopus citations

Abstract

The publisher regrets that an error occurred during the preparation of Figure 1A for final publication. The position of some of the point estimates and the size of the bars representing the confidence intervals were incorrect. An updated version of the article with the correct version of Figure 1A was published online in December 2017. For reference, both the corrected figure that is currently online and the incorrect version of Figure 1A that was published online and in print are shown below.

Original languageEnglish (US)
Pages (from-to)e116-e118
JournalEuropean urology
Volume73
Issue number4
DOIs
StatePublished - Apr 2018

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71] (S0302283817300994) (10.1016/j.eururo.2017.02.010))'. Together they form a unique fingerprint.

Cite this